#Scinai Immunotherapeutics #biopharmaceuticals #inflammation treatment #Israel #Jerusalem

Scinai Immunotherapeutics Achieves Remarkable Financial Milestones in 2024

Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) has recently announced significant advancements in its financial status and business operations for the year 2024. After grappling with a negative shareholders' equity of $7.3 million as of June 30, 2024, the company has made a notable turnaround by achieving a positive equity position of $10 million by September 30, 2024. This transformation follows a successful restructuring that involved converting a substantial loan from the European Investment Bank (EIB) into equity, marking a pivotal milestone in Scinai's financial recovery.

Key Highlights of the Financial Update

On August 21, 2024, Scinai finalized a Loan Restructuring Agreement with the EIB, which included a convert option for its debt. Approximately EUR 26.6 million ($28.1 million) due was exchanged for 1,000 preferred shares. The conversion not only alleviated the burden of debt, reducing the outstanding obligation to $250,000 but it also enhanced the company’s capital structure. As a result, Scinai regained compliance with Nasdaq requirements, a crucial step in maintaining its market standing.

In the nine months ending September 30, 2024, Scinai's reported revenues reached $452 thousand, a substantial increase from zero revenue during the same period in the previous year. This revenue growth is attributed to the commencement of its Contract Development and Manufacturing Organization (CDMO) services.

Growth of CDMO Services

Since January 2024, Scinai has secured work orders totaling around $600K and is currently negotiating contracts with various prospective clients. The company's CDMO unit is positioned to address the growing demand among emerging biotech firms seeking efficient development solutions at competitive prices. The company aims to leverage its advanced contracts to further expand its services.

Scinai has also received backing from the Israeli Innovation Authority, securing grants worth $575,000 aimed at propelling its CDMO business. Further grant applications focus on reimbursement strategies, allowing Scinai to recover a significant portion of its operational costs. Enhanced marketing strategies, including digital outreach and participation in pharmaceutical conferences, aim to boost visibility and attract potential clients.

Research and Development Pipeline

Scinai's commitment to innovation is demonstrated in the research and development sector, as evidenced by its partnership with Germany's Paul Erlich Institute. Following positive feedback on its anti-IL-17A/F nanoAb targeting plaque psoriasis, Scinai plans to commence Phase 1/2a clinical trials in 2025. Preclinical results underscore the efficacy of Scinai's treatment approach, which utilizes nanoAbs to manage psoriatic lesions effectively. These advancements highlight Scinai's focus on addressing significant unmet medical needs in the field of dermatology.

In addition to psoriasis, exploration into nanoAbs targeting other autoimmune diseases is underway, with Scinai actively pursuing collaborations for the ongoing development of these promising treatments. The company holds exclusive options for licenses aimed at commercializing these therapies, further diversifying its product portfolio.

Future Outlook

The company is dedicated to its mission of developing innovative therapeutic solutions, and the recent achievements highlight its potential for substantial growth in the upcoming years. With a renewed financial standing and a robust pipeline of innovative products, Scinai is well positioned to make significant strides in the biopharmaceutical landscape.

As Scinai moves forward, the focus will rest on expanding its client base, enhancing service capabilities within the CDMO unit, and advancing its drug development projects towards successful market entry. Stakeholders and potential investors are encouraged to engage with the company to explore collaboration opportunities and stay updated on its promising journey.

For more information, visit the company’s website or contact their investor relations office.

• ---

This analysis encapsulates the latest developments from Scinai Immunotherapeutics, providing insight into its ongoing ventures and future objectives within the biopharmaceutical arena.